Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Cleveland Clinic
Fred Hutchinson Cancer Center
Vanderbilt-Ingram Cancer Center
Mayo Clinic